Madrigal Pharmaceuticals, Inc.
MDGL
$531.78
-$8.11-1.50%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 256.82% | 432.05% | 864.21% | 3,421.98% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 256.82% | 432.05% | 864.21% | 3,421.98% | -- |
| Cost of Revenue | 630.34% | 800.82% | 1,160.58% | 2,914.94% | -- |
| Gross Profit | 243.73% | 418.84% | 853.05% | 3,445.01% | -- |
| SG&A Expenses | 75.14% | 87.06% | 110.09% | 135.65% | 202.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.74% | 85.62% | 67.74% | 51.46% | 63.48% |
| Operating Income | 26.26% | 39.72% | 43.90% | 41.58% | 6.40% |
| Income Before Tax | 20.98% | 38.12% | 44.26% | 44.77% | 11.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.98% | 38.12% | 44.26% | 44.77% | 11.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.98% | 38.12% | 44.26% | 44.77% | 11.86% |
| EBIT | 26.26% | 39.72% | 43.90% | 41.58% | 6.40% |
| EBITDA | 26.39% | 39.89% | 44.08% | 41.77% | 6.57% |
| EPS Basic | 26.17% | 45.01% | 50.94% | 52.39% | 24.90% |
| Normalized Basic EPS | 26.88% | 45.57% | 51.44% | 52.39% | 24.90% |
| EPS Diluted | 26.17% | 45.01% | 50.94% | 52.39% | 24.90% |
| Normalized Diluted EPS | 26.88% | 45.57% | 51.44% | 52.39% | 24.90% |
| Average Basic Shares Outstanding | 3.64% | 12.37% | 14.22% | 17.99% | 21.70% |
| Average Diluted Shares Outstanding | 3.64% | 12.37% | 14.22% | 17.99% | 21.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |